Literature DB >> 9108863

Infants with Kasabach-Merritt syndrome do not have "true" hemangiomas.

O Enjolras1, M Wassef, E Mazoyer, I J Frieden, P N Rieu, L Drouet, A Taïeb, J F Stalder, J P Escande.   

Abstract

OBJECTIVE: In 1940 Kasabach and Merritt described an infant with a vascular anomaly, extensive purpura, and thrombocytopenia; they called his lesion "capillary hemangioma." Hemangioma is a benign tumor that grows in infancy and is characterized by proliferation of endothelial cells and regression during childhood. Although Kasabach-Merritt syndrome (KMS) is frequently mentioned as a possible complication of hemangioma, our experience suggests that the anatomic vascular lesion underlying the thrombocytopenia is not a "true," classic, involuting type of hemangioma of infancy and childhood. STUDY
DESIGN: We reviewed the clinical and hemostasis data and the response to treatment in 22 cases of KMS, and we analyzed the biopsy specimens of 15 of them.
RESULTS: Clinically none of the 22 patients had classic hemangioma. There was no female preponderance. All patients had severe thrombocytopenia (lowest platelet count = 3000/mm3) and consumption of fibrinogen. Histologically, none had the typical "capillary," involuting type of hemangioma of infancy: they exhibited either a tufted angioma or a kaposiform hemangioendothelioma pattern; all specimens also contained numerous abnormal lymphatic-like vessels; lymphatic malformation was the major component in two patients. The infants exhibited a heterogeneous response to a number of therapeutic regimens, as noted in other reports. Severe morbidity was present; three of our patients died, and one had leg amputation. "Residua" were, in fact, residual vascular neoplasia, variable in duration, and not a stable fibrofatty residuum, as in classic involuted hemangioma; only the hematologic phenomenon was "cured" after a period of years.
CONCLUSIONS: KMS is a distinctive disease of infancy, but the underlying vascular lesion is not a "true," classic, involuting type of hemangioma of infancy. This is a different vascular tumor with a resemblance pathologically to either tufted angioma or kaposiform hemangioendothelioma in association with lymphatic-like vessels. Whether the underlying lesion in KMS is a single anatomic entity or heterogeneous cannot be definitely concluded from this study. We need a better understanding of the pathogenesis of KMS to improve our therapeutic management.

Entities:  

Mesh:

Year:  1997        PMID: 9108863     DOI: 10.1016/s0022-3476(97)70249-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  44 in total

Review 1.  MR imaging of soft tissue tumors and tumor-like lesions.

Authors:  Tal Laor
Journal:  Pediatr Radiol       Date:  2003-12-12

2.  Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.

Authors:  Yvonne E Chiu; Beth A Drolet; Francine Blei; Manuel Carcao; Jason Fangusaro; Michael E Kelly; Alfons Krol; Sabra Lofgren; Anthony J Mancini; Denise W Metry; Michael Recht; Robert A Silverman; Wynnis L Tom; Elena Pope
Journal:  Pediatr Blood Cancer       Date:  2012-02-02       Impact factor: 3.167

Review 3.  Infantile haemangioma: harmless 'strawberry' or life-threatening vascular anomaly?

Authors:  Nerys Roberts
Journal:  Clin Med (Lond)       Date:  2009-08       Impact factor: 2.659

Review 4.  What is new in endothelial neoplasia?

Authors:  David J Papke; Jason L Hornick
Journal:  Virchows Arch       Date:  2019-08-28       Impact factor: 4.064

5.  Morbidity and healthcare costs of vascular anomalies: a national study.

Authors:  Jina Kim; Zhifei Sun; Harold J Leraas; Uttara P Nag; Ehsan Benrashid; Alexander C Allori; Waleska M Pabon-Ramos; Henry E Rice; Cynthia K Shortell; Elisabeth T Tracy
Journal:  Pediatr Surg Int       Date:  2016-11-22       Impact factor: 1.827

6.  Subtotal splenic embolization is a safe and effective treatment for isolated splenic vascular tumors associated with consumptive coagulopathy.

Authors:  Eric H Raabe; Jeffrey R Keefer; Sally E Mitchell; Kelvin Hong; Marc DiFazio; John J Strouse
Journal:  J Pediatr Hematol Oncol       Date:  2011-07       Impact factor: 1.289

7.  Kasabach-Merritt syndrome combined with hypercalcemia: A case report.

Authors:  Runying Zou; Fang Peng; Tian Yu; Saizhen Zeng; Yalan You; Keke Chen; Hui Zou; Xin Tian; Chengguang Zhu; Xiangling He
Journal:  Exp Ther Med       Date:  2017-10-18       Impact factor: 2.447

8.  Kasabach merritt syndrome: management with interferon.

Authors:  Sandhya Acharya; Kalyani Pillai; Abel Francis; S Criton; V K Parvathi
Journal:  Indian J Dermatol       Date:  2010 Jul-Sep       Impact factor: 1.494

9.  Artesunate inhibits proliferation and invasion of mouse hemangioendothelioma cells in vitro and of tumor growth in vivo.

Authors:  Ning Wang; Hongxia Chen; Yinping Teng; Xionghui Ding; Huan Wu; Xianqing Jin
Journal:  Oncol Lett       Date:  2017-09-18       Impact factor: 2.967

Review 10.  Classification and imaging of vascular malformations in children.

Authors:  Laurence J Abernethy
Journal:  Eur Radiol       Date:  2002-12-12       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.